{
  "title": "Paper_674",
  "abstract": "pmc PLoS One PLoS One 440 plosone plos PLOS One 1932-6203 PLOS PMC12469358 PMC12469358.1 12469358 12469358 41004560 10.1371/journal.pone.0330731 PONE-D-25-32151 1 Research Article Medicine and Health Sciences Pharmacology Drug Interactions Biology and Life Sciences Physiology Cardiovascular Physiology Angiogenesis Biology and Life Sciences Developmental Biology Angiogenesis Biology and Life Sciences Immunology Immune Response Inflammation Medicine and Health Sciences Immunology Immune Response Inflammation Medicine and Health Sciences Clinical Medicine Signs and Symptoms Inflammation Biology and Life Sciences Anatomy Ocular System Ocular Anatomy Cornea Medicine and Health Sciences Anatomy Ocular System Ocular Anatomy Cornea Medicine and Health Sciences Medical Conditions Inflammatory Diseases Physical Sciences Chemistry Chemical Compounds Esters Medicine and Health Sciences Clinical Medicine Signs and Symptoms Edema Biology and Life Sciences Toxicology Toxicity Medicine and Health Sciences Pathology and Laboratory Medicine Toxicology Toxicity Synthesis of novel phenoxyacetohydrazide compounds and evaluation therapeutic potential exhibit as anti-inflammatory and anti-angiogenic non https://orcid.org/0000-0003-1086-7292 Mohammed Yasser Hussein Issa Conceptualization Writing â€“ original draft  1 * https://orcid.org/0000-0003-0723-5622 Shntaif Ahmed Hassen Methodology Writing â€“ review & editing  2 Alghamdi Saad Resources  3 Mansour Ahd A. Project administration  4 Qusty Naeem F. Supervision  5 Sindi Azhar S. Formal analysis  5 https://orcid.org/0000-0001-6650-9158 Babalghith Ahmad O. Supervision  6 Bamagous Ghazi A. Visualization  7 Abu-Seer Eman Adnan Data curation  8 1 Department of Pharmacy, Collage of Medicine and Health Science, Hajjah University, Hajjah, Yemen 2 Department of Chemistry, College of Science for Women, University of Babylon, Alhilla, Iraq 3 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia 4 Medical Laboratory Science Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia 5 Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia 6 Medical genetics Department College of Medicine Umm alqura university, Makkah, Saudi Arabia 7 Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia 8 Epidemiology department, Faculty of Public Health and Health informatics, Umm Al-Qura University, Makkah, Saudi Arabia Shaik Afzal Basha Editor  Vignan Pharmacy College, INDIA Competing Interests: * E-mail: issayasser16@gmail.com 26 9 2025 2025 20 9 496058 e0330731 13 6 2025 5 8 2025 26 09 2025 27 09 2025 29 09 2025 Â© 2025 Mohammed et al 2025 Mohammed et al https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License This study aimed to design, synthesize, and evaluate novel morpholine-substituted phenoxyacetohydrazide derivatives as potential anti-inflammatory and anti-angiogenic agents. The compounds were synthesized and characterized by FTIR, NMR, mass spectrometry, and elemental analysis. In silico molecular docking revealed that compound 6e 6e 6e 6e The author(s) received no specific funding for this work. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Data Availability All relevant data are within the manuscript and its Supporting Information Data Availability All relevant data are within the manuscript and its Supporting Information Introduction Inflammation is a vital physiological response that serves as a defense mechanism against harmful stimuli such as pathogens, tissue injury, and irritants. Characterized by symptoms like erythema, edema, increased temperature, and pain, inflammation plays a central role in the healing process [ 1 4 5 6 7 8 7 9 10 11 12 7 13 14 15 Angiogenesis is associated with Chronic inflammation in various pathological conditions by blood vessel proliferation and enlargement and changes in vessel phenotype. Key pro-inflammatory cytokinesâ€”such as TNF-Î± and IL-1Î²â€”are known to induce endothelial proliferation and migration. Another link between inflammation and angiogenesis is provided Inflammatory mediators (e.g., prostaglandins from COX-2 activity) directly upregulate VEGF expression by the prostaglandin E series through COX-2 in several cell types. [ 16 17 20 21 33 17 34 35 In the present study, a molecular hybridization strategy was used to develop novel hybrids of phenoxyacetohydrazide by introducing benzyl and morpholine moieties to enhance their anti-angiogenic and anti-inflammatory activities. These modifications at the structural level were logically developed and implemented in a stepwise manner to enhance drug-like characters such as lipophilicity, receptor affinity, and pharmacokinetic profiles. Directed synthesis of morpholine-substituted compounds was driven by the predicted relationship between structural attributes and improved bioactivity . Materials and methods Chemistry The chemicals used in this study were obtained from Aldrich Chemical Co. Thin-layer chromatography (TLC) was carried out on silica plates backed with aluminum, and the spots were visualized under UV light. Melting points were determined using a Thomas Hoover capillary melting point apparatus equipped with a digital thermometer. Infrared (IR) spectra were recorded using the potassium bromide (KBr) pellet method on an FT-IR Shimadzu 8300 spectrophotometer. Nuclear magnetic resonance (NMR) spectra were measured on a Bruker 400 MHz NMR spectrophotometer in DMSO, with chemical shifts reported in parts per million (ppm) relative to tetramethylsilane as a reference. Mass spectra were obtained using a VG70-70H spectrophotometer, and major fragments are reported with their relative intensities in parentheses. Elemental composition results obtained through X-ray fluorescence (XRF) analysis were within 0.4% of theoretical values. General synthetic procedure for phenoxy acetic/butyric acid ethyl ester derivatives (3aâ€“h) The starting ester derivatives were synthesized by the reaction of (0.05â€‰mol) substituted phenols 1aâ€“h 2aâ€“b 3aâ€“h 13 (4-Chloro-phenoxy)-acetic acid ethyl ester (3a). Yield 83%; FT-IR (cm -1 1 3 3 2 ester 2 Ar Ar + 10 11 3 (4-Bromo-phenoxy)-acetic acid ethyl ester (3b). Yield 87%; FT-IR (cm -1 1 3 3 2ester 2 J Ar J Ar + 10 11 3 O-tolyloxy-acetic acid ethyl ester (3c). Yield 83%; FT-IR (cm -1 1 3ester 3 2 ester 2 J Ar J Ar J Ar + 11 14 3 (2,6-Dimethyl-phenoxy)-acetic acid ethyl ester (3d). Yield 89%; FT-IR (cm -1 1 3 3 2ester 2 Ar 12 16 3 4-(4-Fluoro-phenoxy)-butyric acid ethyl ester (3e). Yield 85%; FT-IR (cm -1 1 3 (t, 3H, CH 3ester 2 2 2 2 ester J Ar J Ar + 12 15 3 (2,4-Diisopropyl-phenoxy)-acetic acid ethyl ester (3f). Yield 89%; FT-IR (cm -1 1 3 3 3 3ester 2ester 2 Ar 16 24 3 4-(4-Bromo-phenoxy)-butyric acid ethyl ester (3g). Yield 81%; FT-IR (cm -1 1 3 3 ester 2 2 2 2ester J Ar J Ar 12 15 3 4-(3-Nitro-phenoxy)-butyric acid ethyl ester (3h). Yield 82%; FT-IR (cm -1 3 3 2 2 2 2ester J Ar Ar J Ar 12 15 5 General synthetic procedure for phenoxy-acetic acid/butyric acid hydrazide derivatives (4aâ€“h) To the solution of (0.03â€‰mol) ester analogs 3aâ€“h 4a-h 12 13 17 (4-Chloro-phenoxy)-acetic acid hydrazide (4a). Yield 89%; mp 116âˆ’118 Â°C; FT-IR (KBr, cm -1 2 1 3 2 2 J Ar J Ar + 8 9 2 2 (4-Bromo-phenoxy)-acetic acid hydrazide (4b). Yield 91%; mp 119â€“120 Â°C; FT-IR (KBr, cm -1 2 1 3 2 2 J Ar J Ar + 8 9 2 2 O-tolyloxy-acetic acid hydrazide (4c). Yield 79%; mp 116-118 o âˆ’1 2 1 3 3 2 2 J Ar J Ar J Ar 9 12 2 2 2-(2,4-Dimethylphenoxy)acetohydrazide (4d). Yield 85%; mp 111â€“113 Â°C; FT-IR (KBr, cm -1 2 1 3 3 2 2 Ar 10 14 2 2 4-(4-Fluoro-phenoxy)-butyric acid hydrazide (4e). Yield 93%; mp 82â€“84 Â°C; FT-IR (KBr, cm -1 2 1 3 2 2 2 2 Ar Ar 10 13 2 2 2-(2, 4-Diisopropylphenoxy)acetohydrazide (4f). Yield 85%; mp 111â€“113 Â°C; FT-IR (KBr, cm -1 2 1 3 3 3ester 2 2 Ar 14 22 2 2 4-(4-Bromo-phenoxy)-butyric acid hydrazide (4g). Yield 78%; mp 87â€“88 Â°C; FT-IR (KBr, cm -1 2 3 2 2 2 2 J Ar J Ar 10 13 2 2 4-(3-Nitro-phenoxy)-butyric acid hydrazide (4h). Yield 76%; mp 92â€“94 Â°C; FT-IR (KBr, cm -1 2 1 3 2 2 2 2 J Ar Ar J Ar 10 13 3 4 General synthetic procedure for phenyl 2-(4-benzylmorpholine-2-carbonyl) hydrazine-1-carboxylate (6e-h) A solution comprising (2 mmol) of phenoxy-acetic acid/butyric acid hydrazide derivatives (4aâ€“m) along with (30â€‰ml) dry DCM at 25â€“30 Â°C, was treated with (3 mmol) lutidine, followed by the addition of (2 mmol) of 4-benzylmorpholine-2-carboxylic acid. The resulting mixture was then stirred for 30â€‰min, then cooled to 0â€“5 Â°C and TBTU (2 mmol) was added drop wise for 30â€‰min with kept the temperature below 5 Â°C. The reaction mass kept overnight with constant stirring was accomplished and monitored by TLC using the mixture (ethyl acetate:Hexane 4:1). The solvent was evaporated under reduced pressure, after added crushed ice, the resulting precipitate was filtered, dried, and subsequently crystallized from ethanol to afford compounds 6aâ€“h 12 4-Benzyl-Nâ€™-(2-(4-chlorophenoxy)acetyl)morpholine-2-carbohydrazide (6a). Yield 72%; M.P112 - 114 Â°C; FT-IR (KBr, cm -1 1 J 2morpholine ring 2 J morpholine ring J 2 morpholine ring 2 Ar 20 22 3 4 4-Benzyl-Nâ€™-(2-(4-bromophenoxy)acetyl)morpholine-2-carbohydrazide (6b). Yield 82%; M.P 124â€“126 Â°C; FT-IR (KBr, cm -1 amide 1 J 2 morpholine ring 2 J morpholine ring J 2morpholine ring 2 Ar 13 d6 20 22 3 4 4-Benzyl- Nâ€™-(2-(o-tolyloxy)acetyl)morpholine-2-carbohydrazide (6c). Yield 77%; M.P 160â€“162 Â°C; FT-IR (KBr, cm -1 1 J 2morpholine ring 2 J morpholine ring J 2 morpholine ring 2 Ar 13 21 25 3 4 4-Benzyl-Nâ€™-(2-(2,4-dimethylphenoxy)acetyl)morpholine-2-carbohydrazide (6d). Yield 84%; M.P 110â€“112 Â°C; FT-IR (KBr, cm -1 amide 1 3 J 2morpholine ring 2 J morpholine ring J 2 morpholine ring 2 Ar 13 + 22 27 3 4 4-Benzyl-Nâ€™-(4-(4-fluorophenoxy)butanoyl)morpholine-2-carbohydrazide (6e). Yield 91%; M.P 115â€“117 Â°C; FT-IR (KBr, cm -1 amide 1 2 J 2 morpholine ring 2 J 2 J morpholine ring Ar 13 + 22 26 3 4 4-Benzyl-Nâ€™-(2-(2,4-diisopropylphenoxy)acetyl)morpholine-2-carbohydrazide (6f). Yield 83%; M.P 244â€“246 Â°C; FT-IR (KBr, cm -1 amide 1 3 J 2morpholine ring 3 3 2 J morpholine ring J 2morpholine ring Ar 13 + 26 35 3 4 4-Benzyl-Nâ€™-(4-(4-bromophenoxy)butanoyl)morpholine-2-carbohydrazide (6g). Yield 77%; M.P 117â€“119 Â°C; FT-IR (KBr, cm -1 amide 1 2 J 2morpholine ring 2 J 2 J morpholine ring Ar 13 22 26 3 4-Benzyl-Nâ€™-(4-(3-nitrophenoxy)butanoyl)morpholine-2-carbohydrazide (6h). Yield 76%; M.P 199â€“201 Â°C; FT-IR (KBr, cm -1 amide 1 J 2morpholine ring 2 J 2 J morpholine ring Ar 13 + 22 26 4 6 ADMET In the current study, we assessed the ADMET (Adsorption, Distribution, Metabolism, Excretion, and Toxicity) properties of each of the four selected molecules using the Swiss ADME ( http://www.swissadme.ch http://lmmd.ecust.edu.cn/admetsar2/ Molecular docking analysis The in silico 6e 36 6e 6e Protein preparation Pre-processing of the protein structures was performed with the Molecular Operating Environment (MOE) software. Protein structures underwent standard bioinformatics pre-processing, which included the It involved adding missing hydrogen atoms and incomplete residues since these components are very essential in maintaining the protein chainâ€™s structural integrity. Further, specific protonation states were assigned, considering a physiological pH of 7.2, thus enabling more realistic modelling of interactions. A crucial part of the preparation was the removal of all heteroatoms, which could interfere with the docking simulations. The energy minimization and geometry optimization using the CHARMM force field was indispensable. The smart minimizer technique, which combines steepest descent and conjugate gradient algorithms, ensured that the potential energy of the system was reduced while keeping the proteins structurally stable deletion of crystallographic water molecules and energy minimization to yield stable conformations acceptable for docking simulations. Compound 6e 37 38 Ligand preparation The two-dimensional structure of compound 6e was built using ACD/ChemSketch and minimize its free energy of the of ligand was done in Steepest Descent and Conjugate Gradient methods using Discovery Studio 2024 Client Software Inc.) The minimized structure was imported into the MOE software. The two-dimensional structure was then converted to a three-dimensional model, and appropriate protonation states at physiological pH were assigned. Biology Human red blood cells (HRBC) membrane stabilization assay The human red blood cell (HRBC) membrane stabilization method was employed to evaluate the anti-inflammatory activity of the compounds, as previously described [ 17 39 40 in vitro 6e-h ğ© ğ ğ« ğœ ğ ğ§ ğ­  ğ© ğ« ğ¨ ğ­ ğ ğœ ğ­ ğ¢ ğ¨ ğ§ = 1 0 0 âˆ’ ( ( ğ ğƒ  ğ¨ ğŸ  ğ ğ« ğ® ğ   ğ­ ğ« ğ ğš ğ­ ğ ğ  ğ¬ ğš ğ¦ ğ© ğ¥ ğ / ğ ğƒ  ğ¨ ğŸ  ğœ ğ¨ ğ§ ğ­ ğ« ğ¨ ğ¥ )  Ã— 1 0 0 ) . In vivo The in vivo 7 Group I â€“ Normal [PBS (Phosphate buffer saline) (10â€‰mM Sodium phosphate mono basic+ 1.8â€‰mM Sodium phosphate dibasic+140â€‰mM sodium chloride, pH 7.4) alone] Group II â€“ Control [1Âµg of rVEGF165 alone] Group III â€“ 5 Âµg of 6e A rectangular window was made in the egg shell and Whatman filter paper (3â€‰mm diameter) containing with or without compound 6e Animals and ethics Animals and ethical approval. Swiss albino female rats, matured by 150âˆ’160â€‰g were housed under standard research Center which to encourage the eating routine of animal food and water which is not obligatory in the complete analysis. The Rats were kept up at the room temperature (27 Â°Câ€‰Â±â€‰2oC) with excellent ventilation for a 12â€‰h day/night cycle. Swiss albino rats (150 gm. Each) were utilized for the current examination. They were encouraged with a standard pellet diet and for which water was not obligatory. All the animals were acclimatized for things like a multi-week identity before the trial session. All animal experimentation was endorsed by the Institutional Animal Ethics Committee (IAEC), (Approval ID: HU-PHARM-ETHICS-2024â€“001). College of Medicine and Health Sciences, Hajjah University, Yemen. Efforts were made to minimize animal suffering, including the use of ketamine/xylazine anesthesia for invasive procedures. Humane endpoints were applied, and animals were euthanized by sodium pentobarbital (â‰¥100â€‰mg/kg, intraperitoneally) followed by cervical dislocation, as per ethical guidelines. Determination of the Lethal Dose 50 (LD50) of the 6e-h The acute lethal dose 50 (LD50) toxicity test is performed in rodents as part of the safety assessment of many substances. The LD50 (median lethal dose) test is usually the first test conducted for every chemical before further toxicity tests are carried out. It is used for estimating the potential hazards of chemicals on humans [ 41 11 13 Induction of alkali burn-induced corneal neovascularization. Corneal neovascularization (CNV) was induced through alkali injury following a standard protocol with minor modifications [ 13 Group I Group II Group III 6e An alkali burn was induced in the right eye of animals in Groups II and III after administering general anesthesia via intraperitoneal injection of ketamine (1â€‰ml/kg) and chlorpromazine (1â€‰ml/kg). A 3-mm diameter piece of Whatman filter paper soaked in 4â€‰ml of 1â€‰mol/L NaOH was applied to the center of the cornea for 30 seconds, followed by irrigation of the treated cornea with 60â€‰ml of normal saline. Group II animals were subsequently treated with 1 Âµg of rVEGF applied to the right eye. The extent of CNV was quantified through photographic documentation 48 hours after the alkali burn and rVEGF treatment. For Group III animals, the alkali-burned cornea was treated with compound 6e 6e 6e Carrageenan-induced Paw Edema in rat Female Swiss albino rats were selected for the study to evaluate the anti-inflammatory effects of compound 6e 25 Group 1 Group 2 Group 3 Group 4 6e Prior to the experiment, animals in Group 2 were administered saline (5â€‰mL/kg), animals in Group 3 received the positive control indomethacin (10â€‰mg/kg), and animals in Group 4 were treated with compound 6e After this period, animals in the 2, 3 and 4 groups were in intraperitoneal with 100 Âµl of 2% carrageenan into the right hind paw to induce edema. The right paws of all experimental animals were then observed at different time intervals (2, 3 and 5 hours post-carrageenan injection), and the paw volume was measured using a digital plethysmometer to assess the degree of edema. Tissue myeloperoxidase activity (MPO) assays Rats were treated either with or without positive control (indomethacin at 10â€‰mg/kg body weight) or compound 6e 42 43 Results and discussion Structure-activity relationship of 4-Benzyl-Nâ€™-(4-(4 fluorophenoxy)butanoyl)morpholine-2-carbohydrazide The morpholine ring provides a rigid, heterocyclic scaffold that likely contributes to the compoundâ€™s overall pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME). Its conformational rigidity might be important for optimal interaction with the target protein(s) involved in the inflammatory response. Also, the benzyl group at the 4-position of the morpholine ring enhances lipophilicity, potentially improving membrane permeability and facilitating interaction with intracellular targets. The aromatic ring also offers the possibility of Ï€-Ï€ stacking interactions with target proteins. Moreover, the butanoyl chain introduces flexibility and length between the morpholine core and the fluorophenoxy group. This spacer crucial for achieving the optimal distance and orientation for interaction with the binding site of the target protein. The length of the spacer influences the compoundâ€™s ability to reach and interact with specific regions of the target. The fluorophenoxy group introduces several important properties as Increases lipophilicity, potentially improving membrane permeability and bioavailability. So, the fluorine atom which is electron-withdrawing, which may subtly alter the electronic distribution within the molecule, potentially influencing its interaction with target proteins. This affect binding affinity and selectivity. Further, the fluorine substitution can enhance metabolic stability by reducing the susceptibility to enzymatic degradation. This led to a longer half-life and improved efficacy. In contrast, these same substitutions were associated with a higher predicted probability of blood-brain barrier (BBB) penetration and P-glycoprotein inhibition, both of which may contribute to increased predicted toxicity and a higher likelihood of drugâ€“drug interactions. Additionally, derivatives with multiple rotatable bonds and higher molecular flexibility tended to show reduced Caco-2 permeability and moderate acute toxicity predictions, as indicated in Table 1 6e Fig 1 10.1371/journal.pone.0330731.t001 Table 1 Retrieved from the PDB database are the physiochemical characteristics of 1RV6. Physiochemical Properties of Protein (1RV6) Parameters Value Cell Space Group P 21 21 21 Crystallographic Resolution 2.5 Ã… Molecular Weight 11.609 kDa Amino-acid Chain Name A, B (we used chain A) Number of Amino-acid Residues 95 10.1371/journal.pone.0330731.g001 Fig 1 Chemical structure of 2-phenoxyacetohydrazide. Synthetic strategy and structural characterization of novel phenoxyacetohydrazide derivatives (6e-h) The synthetic route to target phenyl 2-(4-benzylmorpholine-2-carbonyl) hydrazine-1-carboxylate (6e-h) Scheme 1 3aâ€“h 1aâ€“g 2aâ€“b 3aâ€“h 6e-h 10.1371/journal.pone.0330731.g033 Scheme 1 Synthesis of novel phenoxyacetohydrazide derivatives (6e-h). Investigating the impact of protein size and structure on the binding of compound 6e to VEGF, COX-1, and COX-2 This study investigated the potential interactions of compound 6e Docking study outcomes are summarized qualitatively through visualizations and quantitatively through analysis of the physiochemical parameters enumerated in Tables 2 3 10.1371/journal.pone.0330731.t002 Table 2 Retrieved from the PDB database are the physiochemical characteristics of 1EQG. Physiochemical Properties of Protein (1EQG) Parameters Value Cell Space Group P 21 21 21 Crystallographic Resolution 2.61 Ã… Molecular Weight 137.93 kDa Amino-acid Chain Name A, B (we used chain A) Number of Amino-acid Residues 580 10.1371/journal.pone.0330731.t003 Table 3 Retrieved from the PDB database are the physiochemical characteristics of 1CVU. Physiochemical Properties of Protein (1CVU) Parameters Value Cell Space Group P I 2 2 2 Crystallographic Resolution 2.40 Ã… Molecular Weight 132.6 kDa Amino-acid Chain Name A, B (we used chain A) Number of Amino-acid Residues 552 Ribbon diagrams ( Figs 2â€“ 4 Figs 5â€“ 7 6e 6e 10.1371/journal.pone.0330731.g002 Fig 2 Ribbon representation of the crystal structure of vascular endothelial growth factor-A (VEGF-A), retrieved from the Protein Data Bank (PDB ID: 1RV6). 10.1371/journal.pone.0330731.g003 Fig 3 Visualization of the binding site of vascular endothelial growth factor-A (VEGF-A) (PDB ID: 1RV6). 10.1371/journal.pone.0330731.g004 Fig 4 Ribbon representation of the crystal structure of cyclooxygenase-1 (COX-1) retrieved from the Protein Data Bank (PDB ID: 1EQG). 10.1371/journal.pone.0330731.g005 Fig 5 Visualization of the binding site of COX-1 (PDB ID: 1EQG). 10.1371/journal.pone.0330731.g006 Fig 6 Ribbon representation of the crystal structure of cyclooxygenase-2 (COX-2) retrieved from the Protein Data Bank (PDB ID: 1CVU). 10.1371/journal.pone.0330731.g007 Fig 7 Visualization of the binding site of COX-2 (PDB ID: 1CVU). Evaluating the ADMET landscape of compound 6e: Balancing therapeutic potential and safety considerations This study investigated the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) along with properties under Lipinskiâ€™s Rule of Five (RO5) properties of compound 6e Table 4 6e 10.1371/journal.pone.0330731.t004 Table 4 Comprehensive ADMET profile of compound 6e. Properties Molecule 6e  Formula C 22 26 3 4  MW 415.46â€‰g/mol  Heavy atoms 30  Aromatic heavy atoms 12  Rotatable bonds 11  H-bond acceptors 6  H-bond donors 2  Fraction Csp3 0.36  MR 112.43  TPSA 79.90 Ã…Â²  Consensus Log P 2.53  Octanol/water partition coefficient(logP) 2.75  Aqueous solubility LogS âˆ’3.45  Ali Class Soluble  Silicos-IT LogS âˆ’6.42  Silicos-IT class Soluble  log Kp (cm/s) âˆ’7.18  Lipinski #violations 0  Bioavailability Score 0.55  GPCR ligand âˆ’3.65  Molecular refractivity 112.43 With zero Lipinski violations and a bioavailability score of 0.55, it demonstrates suitable drug-likeness. Its molecular refractivity (112.43) and 11 rotatable bonds indicate potential for favorable target interactions. ADMET predictions indicate high human intestinal absorption (HIAâ€‰+â€‰, 0.9475) and blood-brain barrier penetration (BBBâ€‰+â€‰, 0.9113), though the low Caco-2 permeability (0.7022) introduces uncertainty. However, the prediction suggests low Caco-2 permeability (Caco2-, 0.7022 probability), which seems contradictory to the HIA prediction and warrants further investigation. The carcinogenicity prediction is non-required (0.5288 probability), indicating a moderate uncertainty in this aspect. The acute oral toxicity prediction classifies it as class III (0.6673 probability), suggesting moderate toxicity. The predicted LD50 (2.4760â€‰mol/kg in rats) requires careful consideration and experimental validation as shown in Table 5 10.1371/journal.pone.0330731.t005 Table 5 Toxicity profile analysis of compound 6e insights from ADMET â€œSARâ€ predictions for safer drug development. Model 6e  Blood-Brain Barrier Result BBB+ Probability 0.9113  P-glycoprotein Inhibitor Result Inhibitor Probability 0.8986  Human Intestinal Absorption Result HIA+ Probability 0.9475  Caco-2 Permeability Result Caco2- Probability 0.7022  Carcinogenicity (Three-class) Result Non-required Probability 0.5288  Acute oral toxicity Result III Probability 0.6673  Rat Toxicity LD50â€‰mol/kg Result LD50, mol/kg Probability 2.4760 Evaluation the network connections, toxicity profile, and distribution characteristics of the compound 6e. The network chart ( Fig 8 6e 6e 6e Fig 9 6e 6e 6e 6e Fig 10 6e 6e 6e Fig 11 6e 6e 10.1371/journal.pone.0330731.g008 Fig 8 Network diagram illustrating the predicted pharmacological activity profile of the 6e compound. 10.1371/journal.pone.0330731.g009 Fig 9 Toxicity radar chart representing the predicted toxicity profile of the 6e compound. 10.1371/journal.pone.0330731.g010 Fig 10 Distribution of dose value of the 6e compound. 10.1371/journal.pone.0330731.g011 Fig 11 Distribution of molecular weight value of the 6e compound. Construction and preparation of the compound 6e This study was focused on designing and preparing compound 6e 6e 6e 6e 6e Fig 12 10.1371/journal.pone.0330731.g012 Fig 12 Chemical structural of the compound 6e. The initial 2D structure was optimized in MOE and converted into a 3D model using Chem3D 16.0. Compound 6e exhibits multifaceted binding interactions with VEGF, COX-1, and COX-2 as revealed through molecular docking analysis. The current study attempts an extensive in silico 6e 6e 6e âˆ’13.1622 6e âˆ’9.2719 This score signifies advantageous binding circumstances, implying that compound 6e âˆ’12.5301 âˆ’12.6705 âˆ’11.7255 âˆ’12.5679 6e 6e Figs 13â€“ 15 6e Fig 13 6e 6e Fig 14 6e 6e Fig 15 Figs 16â€“ 18 6e 6e Fig 17 Figs 19â€“ 21 6e 6e 6e S1 File 6e 6e 6e 6e 6e 6e 6e 10.1371/journal.pone.0330731.g013 Fig 13 A detailed 3D visualization demonstrating the binding interaction of compound 6e (depicted in blue and red) within the active site of the VEGF receptor (PDB ID: 1RV6), represented by green ribbon structures. This illustration highlights the precise fit of compound 6e 10.1371/journal.pone.0330731.g014 Fig 14 A detailed 2D schematic representation illustrating the non-covalent interactions that stabilize the VEGF receptor (PDB ID: 1RV6)-compound 6e complex. This visualization highlights the key hydrogen bonds, hydrophobic interactions, and other stabilizing forces contributing to the assemblyâ€™s structural integrity and binding affinity. 10.1371/journal.pone.0330731.g015 Fig 15 2D interaction of compound 6e (left) and indomethacin drug (right) within the active site of VEGF receptor (PDB ID: 1RV6). 10.1371/journal.pone.0330731.g016 Fig 16 A captivating 3D visualization showcasing the binding interaction of compound 6e (depicted in red) within the active site of the COX-1 receptor (PDB ID: 1EQG). 10.1371/journal.pone.0330731.g017 Fig 17 A detailed 2D schematic representation illustrating the non-covalent interactions that stabilize the COX-1 receptor-6e complex. 10.1371/journal.pone.0330731.g018 Fig 18 2D interaction of compound 6e (left) and indomethacin drug (right) within the active site of cyclooxygenase-1 (COX-1) (PDB ID: 1EQG). 10.1371/journal.pone.0330731.g019 Fig 19 A striking 3D visualization showcasing the binding interaction of compound 6e (depicted in red) within the active site of the COX-2 receptor (PDB ID: 1CVU). 10.1371/journal.pone.0330731.g020 Fig 20 A detailed 2D schematic representation illustrating the non-covalent interactions stabilizing the COX-2 receptor (PDB ID: 1CVU)-compound 6e complex. 10.1371/journal.pone.0330731.g021 Fig 21 2D interaction of compound 6e (left) and indomethacin drug (right) within the active site of cyclooxygenase-2 (COX-2) (PDB ID: 1CVU). In Vitro An in vitro HRBC membrane stabilization assay was conducted to evaluate the anti-inflammatory potential of eight synthesized compounds (6a-h). The assay measures the ability of a compound to prevent the lysis of HRBC membranes under stress, indirectly indicating anti-inflammatory activity. Results are expressed as â€œIC50â€ values (Âµg/ml), representing the concentration needed to inhibit 50% of membrane lysis. Lower â€œIC50â€ values indicate greater potency. Compound 6e 155 . Table 6 10.1371/journal.pone.0330731.t006 Table 6 IC 50 p Samples HRBC membrane stabilization â€œIC50â€ Value (Âµg/ml) Control â€“ 6a 311 6b 222 6c 289 6d 199 6e 155.199 6f 301 6g 279 6h 255 Moreover, the anti-inflammatory potential of compound 6e 6e 6e Table 7 6e 6e Also, t 6e 6e 10.1371/journal.pone.0330731.t007 Table 7 in-vitro Sample Concentration (Âµg) Absorbance at 560nm % Inhibition â€œIC50â€ (Âµg/ml) Control â€“ 0.912â€‰Â±â€‰0.012 â€“ Indomethacin 50 0.601â€‰Â±â€‰0.003 33.10 122.01 Compound 6e 50 0.702â€‰Â±â€‰0.001 28.88 165.988 The results from the HRBC membrane stabilization assay demonstrate that compound 6e 6e 6e Compound 6e exhibits potent anti-angiogenic effects by inhibiting VEGF-Induced vascular formation. The effects of compound 6e in vivo ex vivo Figs 22â€“ 27 6e 6e 6e Fig 22 10.1371/journal.pone.0330731.g022 Fig 22 Effect of 6e on rVEG F165 induced in vivo CAM. images of the chorioallantoic membrane (CAM) from fertilized chicken eggs after treatment. Left image (Negative Control): Dense and highly branched neovasculature (black arrows) visible within the yellow demarcation zone, indicating active angiogenesis. Middle image (Positive Control or Standard Treatment): Moderate reduction in vessel density and branching. Right image (Compound 6e-treated group): Marked suppression of neovascularization with sparse, thin, and poorly branched blood vessels, demonstrating significant anti-angiogenic potential. 10.1371/journal.pone.0330731.g023 Fig 23 H&E staining of in vivo Representative histological sections of corneal tissue from experimental groups stained with hematoxylin and eosin: Left image (Negative control): Extensive neovascularization (black arrows) and inflammatory cell infiltration are observed in the stromal layer. Middle image (Indomethacin-treated group): Moderate reduction in neovascular structures (black arrows) and inflammatory cells, with partially restored corneal architecture. Right image (Compound 6e-treated group): Marked improvement in corneal structure with minimal inflammatory infiltration and absence of neovessel, indicating significant anti-inflammatory and anti-angiogenic effects. 10.1371/journal.pone.0330731.g024 Fig 24 Total vessel length of in vivo Each value is expressed as meanâ€‰Â±â€‰SD ( p 10.1371/journal.pone.0330731.g025 Fig 25 Effect of 6e on rVEG F165 induced ex-in vivo CAM assay. Left image (Controlâ€‰+â€‰VEGF): Dense and highly branched vasculature (black arrows) radiating from the central embryo, indicating robust VEGF-induced angiogenesis. Middle image (Standard treatment): Moderate reduction in vessel branching and density, consistent with partial anti-angiogenic activity. Right image (Compound 6e-treated group): Marked suppression of new blood vessel formation with sparse and thin vascular branches, indicating significant anti-angiogenic potential of compound 6e 10.1371/journal.pone.0330731.g026 Fig 26 H&E staining of ex-vivo Left image (Controlâ€‰+â€‰VEGF): Extensive neovessel formation (black arrows) and infiltration of inflammatory cells into the mesodermal layer, indicating strong pro-angiogenic response. Middle image (Standard treatment): Moderate vascular proliferation and inflammation with partial normalization of tissue architecture. Right image (Compound 6e 6e 10.1371/journal.pone.0330731.g027 Fig 27 Total vessel length of ex-vivo Each value is expressed as meanâ€‰Â±â€‰SD (pâ€‰<â€‰pâ€‰<â€‰0.0001versus control, nâ€‰=â€‰6). Fig 23 in vivo 6e 6e Fig 24 Fig 22 6e 6e Also, Fig 25 ex vivo Similar to the in vivo ex vivo Fig 26 Fig 27 6e In conclusion, the results from the in vivo in vivo in vivo ex vivo 6e Anti-inflammatory and antiangiogenic effects of compound 6e in a CNV of rat model The corneal alkali burn model is a well-established and highly reliable experimental tool for the assessment of pharmacological agentsâ€™ effects on inflammatory angiogenesis. As early as three days after the corneal alkali injury, the development of CNV was seen in both the control and the compound 6e Fig 28 6e 6e Fig 28a 28b 6e Fig 28c 6e 6e 6e 6e 6e 10.1371/journal.pone.0330731.g028 Fig 28 Angiogenesis modulatory effect of compound 6e on neovascularization (a) Representative photographs of the rat cornea illustrating the inhibition of angiogenesis in alkali-burnt corneas following treatment with compound 6e. (b) Hematoxylin and eosin (H&E) staining of the cornea reveals improved corneal structure and morphology after treatment with compound 6e 6e Anti-edema effect of compound 6e on carrageenan-induced paw edema in rats This study investigated the anti-edema effect of compound 6e Fig 29 6e 6e 6e 6e 6e Fig 30 Fig 31 6e 6e 6e 6e 6e 6e Fig 29a 29b 6e 6e 6e 10.1371/journal.pone.0330731.g029 Fig 29 Photograph of representative rat of each group showing the effect of treatment on paw edema treated with compound 6e. 10.1371/journal.pone.0330731.g030 Fig 30 H and E staining representative rat changes of each group showing the effect of treatment on paw edema treated with compound 6e. 10.1371/journal.pone.0330731.g031 Fig 31 Effect of treated with compound 6e on carrageenan-induced paw edema in rat. The paw swelling ratio is the percent increase of paw volume. Compound 6e Compound 6e attenuates neutrophil infiltration and MPO in carrageenan-induced paw inflammation In present study investigated the effect of compound 6e Fig 32 6e 6e 6e 6e 6e 10.1371/journal.pone.0330731.g032 Fig 32 Effect of intraperitoneal administration of compound 6e on myeloperoxidase activity in carrageenan-treated paws. This figure illustrates the impact of compound 6e 6e The observed inhibition of MPO activity by compound 6e 6e 6e 6e Fig 31 6e 6e 6e Conclusion This study has succeeded in creating, making, and testing a group of new morpholine-substituted phenoxyacetohydrazide compounds, especially compound 6e 6e 6e 6e 6e 6e 6e 6e 6e 6e 6e 6e 6e in vivo 6e Supporting information S1 File Supplemental 1S, 2S and 3S Tables. (DOCX) The authors would like to acknowledge the support and resources provided by the Department of Pharmacy, College of Medicine and Health Science, Hajjah University, Yemen, for facilitating this research. References 1 Chopra D Shukla S Rana P Kamar MD Gaur P Bala M et al Overview of inflammation. Inflammation resolution and chronic diseases Singapore Springer Nature Singapore 2024 1 18 2 Chen L Deng H Cui H Fang J Zuo Z Deng J et al Inflammatory responses and inflammation-associated diseases in organs Oncotarget 2017 9 6 7204 18 doi: 10.18632/oncotarget.23208 29467962 PMC5805548 3 Abdulkhaleq LA Assi MA Abdullah R Zamri-Saad M Taufiq-Yap YH Hezmee MNM The crucial roles of inflammatory mediators in inflammation: a review Vet World 2018 11 5 627 35 doi: 10.14202/vetworld.2018.627-635 29915501 PMC5993766 4 Ansar W Ghosh S Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease 2016 67 107 5 Qiao H Ren H Liu Q Jiang Y Wang Q Zhang H et al Anti-inflammatory effects of Rehmannia glutinosa polysaccharide on LPS-induced acute liver injury in mice and related underlying mechanisms J Ethnopharmacol 2025 351 120099 doi: 10.1016/j.jep.2025.120099 40484254 6 Puttaswamy N Malojiao VH Mohammed YHE Sherapura A Prabhakar BT Khanum SA Synthesis and amelioration of inflammatory paw edema by novel benzophenone appended oxadiazole derivatives by exhibiting cyclooxygenase-2 antagonist activity Biomed Pharmacother 2018 103 1446 55 doi: 10.1016/j.biopha.2018.04.167 29864929 7 Bennett JM Reeves G Billman GE Sturmberg JP Inflammation-natureâ€™s way to efficiently respond to all types of challenges: implications for understanding and managing â€œthe epidemicâ€ of chronic diseases Front Med (Lausanne) 2018 5 316 doi: 10.3389/fmed.2018.00316 30538987 PMC6277637 8 Fang W Sun W Fang W Zhao S Wang C Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy Int Immunopharmacol 2024 134 112178 doi: 10.1016/j.intimp.2024.112178 38728883 9 Ranganatha VL Vijay Avin BR Thirusangu P Prashanth T Prabhakar BT Khanum SA Synthesis, angiopreventive activity, and in vivo tumor inhibition of novel benzophenone-benzimidazole analogs Life Sci 2013 93 23 904 11 doi: 10.1016/j.lfs.2013.10.001 24135459 10 Tabas I Glass CK Anti-inflammatory therapy in chronic disease: challenges and opportunities Science 2013 339 6116 166 72 doi: 10.1126/science.1230720 23307734 PMC3608517 11 Greco G Agafonova A Cosentino A Cardullo N Muccilli V Puglia C et al Solid lipid nanoparticles encapsulating a benzoxanthene derivative in a model of the human blood-brain barrier: modulation of angiogenic parameters and inflammation in vascular endothelial growth factor-stimulated angiogenesis Molecules 2024 29 13 3103 doi: 10.3390/molecules29133103 38999055 PMC11243179 12 Velazquez OC Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing J Vasc Surg 2007 doi: 10.1016/j.jvs.2007.02.068 17544023 PMC2706093 13 Walsh DA Pearson CI Angiogenesis in the pathogenesis of inflammatory joint and lung diseases Arthritis Res Ther 2001 3 3 147 53 doi: 10.1186/ar292 11299055 PMC128891 14 Mohammed YHI, et al. Anti-angiogenesis compound. U.S. Patent 10,954,200; 2021. 15 Chen F Zhang K Wang M He Z Yu B Wang X VEGF-FGF signaling activates quiescent CD63 liver stem cells to proliferate and differentiate Adv Sci 2024 11 10.1002/advs.202308711 PMC11434209 38881531 16 Yang H He C Bi Y Zhu X Deng D Ran T et al Synergistic effect of VEGF and SDF-1Î± in endothelial progenitor cells and vascular smooth muscle cells Front Pharmacol 2022 13 914347 doi: 10.3389/fphar.2022.914347 35910392 PMC9335858 17 Li Y Liu Y Liu S Gao M Wang W Chen K et al Diabetic vascular diseases: molecular mechanisms and therapeutic strategies Signal Transduct Target Ther 2023 8 1 152 37037849 10.1038/s41392-023-01400-z PMC10086073 18 Semeraro F Morescalchi F Cancarini A Russo A Rezzola S Costagliola C Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications Diabetes Metab 2019 45 6 517 27 doi: 10.1016/j.diabet.2019.04.002 31005756 19 Neve A Cantatore FP Maruotti N Corrado A Ribatti D Extracellular matrix modulates angiogenesis in physiological and pathological conditions Biomed Res Int 2014 2014 756078 doi: 10.1155/2014/756078 24949467 PMC4052469 20 Sayed MM Nabil ZI El-Shenawy NS Al-Eisa RA Nafie MS In Vitro and In Vivo effects of synthesis novel phenoxyacetamide derivatives as potent apoptotic inducer against HepG2 cells through PARP-1 inhibition Pharmaceuticals (Basel) 2023 16 11 1524 doi: 10.3390/ph16111524 38004390 PMC10674780 21 Mezu-Ndubuisi OJ Maheshwari A The role of integrins in inflammation and angiogenesis Pediatr Res 2021 89 7 1619 26 doi: 10.1038/s41390-020-01177-9 33027803 PMC8249239 22 Libby JR Royce H Walker SR Li L The role of extracellular matrix in angiogenesis: beyond adhesion and structure Biomater Biosyst 2024 15 100097 doi: 10.1016/j.bbiosy.2024.100097 39129826 PMC11315062 23 Ullah AAAM Synthesis and evaluation of novel heterocyclic compounds as anticancer agents [Doctoral dissertation]. United Kingdom: University of Salford 2020 24 Ranganatha VL Mallikarjunaswamy C Ramu R Shirahatti PS Kumar N Sowmya BP Design, synthesis, docking, Hirshfeld surface analysis and DFT calculations of 2-methylxanthen-9-with the FtsZ protein from Staphylococcus aureus Bioinformation 2021 17 3 393 34092960 10.6026/97320630017393 PMC8131576 25 Burayk S Oh-Hashi K Kandeel M Drug discovery of new anti-inflammatory compounds by targeting cyclooxygenases Pharmaceuticals (Basel) 2022 15 3 282 doi: 10.3390/ph15030282 35337080 PMC8955829 26 Prabhuswamy A et al Synthesis, crystal structure elucidation, Hirshfeld surface analysis, 3D energy frameworks and DFT studies of 2-(4-fluorophenoxy) acetic acid Eur J Chem 2021 12 304 13 27 Abu-Reidah IM Taamalli A Promising phytoconstituents in antiangiogenesis drug development. Nutraceuticals 2024 450 68 28 Sallam HH et al Synthesis, structure analysis, DFT calculations, Hirshfeld surface studies, and energy frameworks of 6-chloro-3-[(4-chloro-3-methylphenoxy) methyl][1, 2, 4] triazolo [4, 3-b] pyridazine J Mol Struct 2021 1237 130282 29 Khamees HA Mohammed YHE Ananda S Al-Ostoot FH Sangappa Y Alghamdi S Effect of o-difluoro and p-methyl substituents on the structure, optical properties and anti-inflammatory activity of phenoxy thiazole acetamide derivatives: theoretical and experimental studies J Mol Struct 2020 1199 127024 30 Al-Ostoot FH Mohammed YHE Kempaiah AN Khanum SA Synthesis, in silico study and in vitro anti-microbial evaluation of some new N-benzoyl-Nâ€™-[2-(4-chloro-phenoxy)-acetyl]-hydrazides analogs J Appl Pharm Sci 2019 9 7 42 9 31 Sharma G Anthal S Geetha DV Al-Ostoot FH Hussein Eissa Mohammed Y Ara Khanum S et al Synthesis, structure and molecular docking analysis of an anticancer drug of N-(2-aminophenyl)-2-(2-isopropylphenoxy) acetamide Mol Cryst Liq Cryst 2018 675 1 85 95 doi: 10.1080/15421406.2019.1624051 32 Al-Ostoot FH Stondus J Anthal S Venkatesh GD Mohammed YHE Sridhar MA Synthesis, spectroscopic and X-ray crystallographic analysis of N-(2-(2-(4-chlorophenoxy) acetamido) phenyl)-1H-indole-2-carboxamide Eur J Chem 2019 10 3 234 8 33 Al-Ghorbani M Thirusangu P Gurupadaswamy HD Vigneshwaran V Mohammed YHE Prabhakar BT et al Synthesis of novel morpholine conjugated benzophenone analogues and evaluation of antagonistic role against neoplastic development Bioorg Chem 2017 71 55 66 doi: 10.1016/j.bioorg.2017.01.011 28139247 34 Wang X Zhao T Yang B Li Z Cui J Dai Y et al Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists Bioorg Med Chem 2015 23 1 132 40 doi: 10.1016/j.bmc.2014.11.016 25481394 35 Naveen S Naveen P Manjunath HR Lokanath NK Khanum SA Warad I 5-(4-methoxyphenyl)-1, 3, 4-oxadiazol-2-amine IUCrData 2016 1 12 36 Wang W-Z Liu C Luo J-Q Lei L-J Chen M-H Zhang Y-Y et al A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis Acta Pharmacol Sin 2024 45 10 2119 33 doi: 10.1038/s41401-024-01305-9 38811775 PMC11420243 37 Taha M Rahim F Uddin I Amir M Iqbal N Wadood A et al Discovering phenoxy acetohydrazide derivatives as urease inhibitors and molecular docking studies J Biomol Struct Dyn 2024 42 6 3118 27 doi: 10.1080/07391102.2023.2212794 37211867 38 Elgohary MK Abo-Ashour MF Abd El Hadi SR El Hassab MA Abo-El Fetoh ME Afify H et al Novel anti-inflammatory agents featuring phenoxy acetic acid moiety as a pharmacophore for selective COX-2 inhibitors: synthesis, biological evaluation, histopathological examination and molecular modeling investigation Bioorg Chem 2024 152 107727 doi: 10.1016/j.bioorg.2024.107727 39167872 39 Mohammed YHI Shamkh IM Shntaif AH Sufyan M Rehman MT AlAjmi MF et al Synthesis and evaluation of pyridine-3-carboxamide analogs as effective agents against bacterial wilt in tomatoes Sci Rep 2024 14 1 11118 doi: 10.1038/s41598-024-59609-z 38750062 PMC11096348 40 Klepsch F Vasanthanathan P Ecker GF Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors J Chem Inf Model 2014 54 1 218 29 doi: 10.1021/ci400289j 24050383 PMC3904775 41 Bao MH Li GY Huang XS Tang L Dong LP Li JM Long noncoding RNA LINC00657 acting as a miR-590-3p sponge to facilitate low concentration oxidized low-density lipoprotein--induced angiogenesis Mol Pharmacol 2018 93 4 368 75 29436491 10.1124/mol.117.110650 42 Aloufi BH Structure-based multi-targeted molecular docking and molecular dynamic simulation analysis to identify potential inhibitors against ovarian cancer J Biochem Technol 2022 13 2 29 39 43 Youssef AMM Althneibat THA Maaty DAM Gaber Y Antimicrobial and Anti-Inflammatory Potential of Euphorbia paralias (L.): a bioprospecting study with phytoconstituents analysis J Pharmacopuncture 2024 27 3 223 33 doi: 10.3831/KPI.2024.27.3.223 39350926 PMC11439520 ",
  "metadata": {
    "Title of this paper": "Antimicrobial and Anti-Inflammatory Potential of Euphorbia paralias (L.): a bioprospecting study with phytoconstituents analysis",
    "Journal it was published in:": "PLOS One",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469358/"
  }
}